A controlled trial of idebenone in Huntington's disease.
One hundred patients with clinically diagnosed Huntington's disease (HD) were randomized to either idebenone, an antioxidant and enhancer of oxidative metabolism, or placebo, in a 1-year, double-blind, parallel-group study aimed at slowing the rate of progression of the disease. Ninety-one patients completed the study. There were no significant differences between groups on the primary outcome measures of the Huntington's Disease Activities of Daily Living Scale (ADL-an index of functional status) and the Quantified Neurologic Examination (QNE). Sample size calculations based on progression of the ADL and QNE in this study group revealed that a larger study group is necessary to detect any differences less than an almost complete halting of the disease. This argues for multicenter efforts for future therapeutic trials in HD.
Ranen
N G
NG
Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Peyser
C E
CE
Coyle
J T
JT
Bylsma
F W
FW
Sherr
M
M
Day
L
L
Folstein
M F
MF
Brandt
J
J
Ross
C A
CA
Folstein
S E
SE
D000203:Activities of Daily Living; D000328:Adult; D000975:Antioxidants / Q000494:pharmacology* / Q000627:therapeutic use*; D016227:Benzoquinones / Q000494:pharmacology* / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010919:Placebos; D017470:Receptors, Glutamate / Q000187:drug effects; D016896:Treatment Outcome; D014451:Ubiquinone / Q000031:analogs & derivatives
D000975:Antioxidants; D016227:Benzoquinones; D010919:Placebos; D017470:Receptors, Glutamate; D014451:Ubiquinone; C036619:idebenone